Target organ damage in African American hypertension: Role of APOL1

Current Hypertension Reports

Volumn 14, Issue 1, 2012, Pages 21-28

  Freedman, Barry I ^a   Murea, Mariana ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

African American; African sleeping sickness; APOL1; Arteriolar nephrosclerosis; Chronic kidney disease; Dialysis; End stage renal disease; ESRD: Focal segmental glomerulosclerosis; Genetics; Glomerulosclerosis; Hypertension; Hypertensive nephrosclerosis; Kidney disease; Kidney donors; MYH9; Nondiabetic nephropathy; Racial differences; Transplantation; Trypanosoma brucei rhodesiense

Indexed keywords

AMLODIPINE; METOPROLOL; RAMIPRIL;

AFRICAN AMERICAN; AFRICAN TRYPANOSOMIASIS; APOLIPOPROTEIN 1 GENE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHROMOSOME 22Q; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; FOCAL GLOMERULOSCLEROSIS; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HIV ASSOCIATED NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MOLECULAR GENETICS; MYOSIN HEAVY CHAIN 9 GENE; NEPHRITIS; NEPHROSCLEROSIS; PATHOPHYSIOLOGY; PROTEINURIA; RENAL REPLACEMENT THERAPY; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS;

AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOLIPOPROTEINS; COHORT STUDIES; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINURIA; RISK FACTORS; TREATMENT FAILURE;

EID: 84857625518     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0237-4     Document Type: Article

References (75)

1. U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD. 121-132. 2010.
2. BA Kiberd CM Clase 2002 Cumulative risk for developing end-stage renal disease in the US population J Am Soc Nephrol 13 1635 1644 12039993 10.1097/01.ASN.0000014251.87778.01
3. WM McClellan BB Newsome LA McClure, et al. 2010 Poverty and racial disparities in kidney disease: the REGARDS study Am J Nephrol 32 38 46 20516678 10.1159/000313883
4. K Evans J Coresh LD Bash, et al. 2011 Race differences in access to health care and disparities in incident chronic kidney disease in the US Nephrol Dial Transplant 26 899 908 20688771 10.1093/ndt/gfq473
5. G Genovese DJ Friedman MD Ross, et al. 2010 Association of trypanolytic ApoL1 variants with kidney disease in African Americans Science 329 841 845 20647424 10.1126/science.1193032 1:CAS:528:DC%2BC3cXpvV2iu7c%3D This landmark report revealed that two coding variants in the apolipoprotein L1 gene (APOL1), termed G1 and G2, were strongly associated with FSGS and nondiabetic forms of ESRD. These diseases were previously attributed to variation in the adjacent non-muscle myosin heavy chain 9 gene (MYH9). The protein product of nephropathy-associated APOL1 variants lysed Trypanosoma brucei rhodesiense, a cause of African sleeping sickness
6. S Tzur S Rosset R Shemer, et al. 2010 Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene Hum Genet 128 345 350 20635188 10.1007/s00439-010- 0861-0 1:CAS:528:DC%2BC3cXhtVahtrfF This report also revealed that variation in the APOL1 gene contributed to nondiabetic ESRD susceptibility in African Americans. The G1 nephropathy risk variant was detected.
7. BI Freedman JB Kopp CD Langefeld, et al. 2010 The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans J Am Soc Nephrol 21 1422 1426 20688934 10.1681/ASN.2010070730 1:CAS:528:DC%2BC3cXhtF2ksLfK
8. AJ Howie 2011 Problems with 'focal segmental glomerulosclerosis' Pediatr Nephrol 26 1197 1205 21125407 10.1007/s00467-010-1701-0
9. L Zarif A Covic S Iyengar, et al. 2000 Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis Nephrol Dial Transplant 15 1801 1807 11071968 10.1093/ndt/15.11.1801 1:STN:280:DC%2BD3M%2FkvFKnsw%3D%3D
10. BI Freedman SS Iskandar RG Appel 1995 The link between hypertension and nephrosclerosis Am J Kidney Dis 25 207 221 7847347 10.1016/0272-6386(95)90001-2 1:STN:280:DyaK2M7ltVSjsA%3D%3D
11. BI Freedman JR Sedor 2008 Hypertension-associated kidney disease: perhaps no more J Am Soc Nephrol 19 2047 2051 18923054 10.1681/ASN.2008060621
12. SD Schlessinger MR Tankersley JJ Curtis 1994 Clinical documentation of end-stage renal disease due to hypertension Am J Kidney Dis 23 655 660 8172207 1:STN:280:DyaK2c3is1Wkuw%3D%3D
13. TV Perneger PK Whelton MJ Klag KA Rossiter 1995 Diagnosis of hypertensive end-stage renal disease: effect of patient's race Am J Epidemiol 141 10 15 7801960 1:STN:280:DyaK2M7gtVaitg%3D%3D
14. MJ Klag PK Whelton BL Randall, et al. 1996 Blood pressure and end-stage renal disease in men N Engl J Med 334 13 18 7494564 10.1056/NEJM199601043340103 1:STN:280:DyaK287gsFakug%3D%3D
15. B Kestenbaum KD Rudser I de Boer 2008 Differences in kidney function and incident hypertension: the multi-ethnic study of atherosclerosis Ann Intern Med 148 501 508 18378946
16. A Fogo JA Breyer MC Smith, et al. 1997 Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators Kidney Int 51 244 252 8995739 10.1038/ki.1997.29 1:STN:280:DyaK2s7kvV2itg%3D%3D
17. C Marcantoni LJ Ma C Federspiel AB Fogo 2002 Hypertensive nephrosclerosis in African Americans versus Caucasians Kidney Int 62 172 180 12081576 10.1046/j.1523-1755.2002.00420.x
18. NB Shulman CE Ford WD Hall, et al. 1989 Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 I80 I93 2490833 1:STN:280:DyaK3MzhtVaktw%3D%3D
19. WG Walker JD Neaton JA Cutler, et al. 1992 Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group JAMA 268 3085 3091 1433739 10.1001/jama.1992.03490210067037 1:STN:280:DyaK3s%2FlvF2luw%3D%3D
20. BI Freedman JM Soucie WM McClellan 1997 Family history of end-stage renal disease among incident dialysis patients J Am Soc Nephrol 8 1942 1945 9402097 1:STN:280:DyaK1c%2FmtlKruw%3D%3D
21. BI Freedman NV Volkova SG Satko, et al. 2005 Population-based screening for family history of end-stage renal disease among incident dialysis patients Am J Nephrol 25 529 535 16179780 10.1159/000088491
22. BJ Spray NG Atassi AB Tuttle BI Freedman 1995 Familial risk, age at onset, and cause of end-stage renal disease in white Americans J Am Soc Nephrol 5 10 1806 1810 7787148 1:STN:280:DyaK2Mzgs1Omsw%3D%3D
23. BI Freedman 2003 Susceptibility genes for hypertension and renal failure J Am Soc Nephrol 14 7 Suppl 2 S192 S194 12819327 10.1097/01.ASN.0000070075. 89996.4A 1:CAS:528:DC%2BD3sXmt1WitL0%3D
24. BI Freedman BJ Spray AB Tuttle VM Buckalew Jr 1993 The familial risk of end-stage renal disease in African Americans Am J Kidney Dis 21 387 393 8465818 1:STN:280:DyaK3s3itVKktA%3D%3D
25. BI Freedman 2002 End-stage renal failure in African Americans: insights in kidney disease susceptibility Nephrol Dial Transplant 17 2 198 200 11812863 10.1093/ndt/17.2.198
26. BI Freedman 1993 Renal microvascular susceptibility in African American pedigrees Transplant Proc 25 2423 2425 8356620 1:STN:280:DyaK3szmt1ajsA%3D%3D
27. RS Cooper JS Kaufman R Ward 2003 Race and genomics N Engl J Med 348 1166 1170 12646675 10.1056/NEJMsb022863
28. LJ Appel J Middleton ER Miller III, et al. 2003 The rationale and design of the AASK cohort study J Am Soc Nephrol 14 S166 S172 12819323 10.1097/01.ASN.0000070081.15137.C0
29. JT Wright Jr G Bakris T Greene, et al. 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2421 2431 12435255 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D
30. LJ Appel JT Wright Jr T Greene, et al. 2010 Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 918 929 20818902 10.1056/NEJMoa0910975 1:CAS:528:DC%2BC3cXhtFWjsbzN This report contained the final AASK Cohort Study results. Strict blood pressure control using ACE inhibition failed to slow or halt nephropathy progression in African Americans thought to have hypertensive kidney disease and lacking proteinuria. Some benefit was seen in those participants with elevated baseline urinary protein excretion.
31. SM Korbet 2003 Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis Semin Nephrol 23 219 228 12704582 10.1053/snep.2003.50020 1:CAS:528:DC%2BD3sXjsVWisrw%3D
32. BI Freedman JR Sedor 2010 Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 2565 2566 21175324 1:CAS:528:DC%2BC3cXhs1WhtLzL
33. B Astor MS Lipkowitz WHL Kao R Parekh MH Choi JB Kopp LJ Appel Cheryl Winkler GW Nelson 2010 MYH9 variations are associated with chronic kidney disease progression in the African American Study of Hypertension and Kidney Diseases [abstract] J Am Soc Nephrol 21 81A
34. MW Smith N Patterson JA Lautenberger, et al. 2004 A high-density admixture map for disease gene discovery in African Americans Am J Hum Genet 74 1001 1013 15088270 10.1086/420856 1:CAS:528:DC%2BD2cXjvVeisLk%3D
35. J Divers S Moossavi CD Langefeld BI Freedman 2008 Genetic admixture: a tool to identify diabetic nephropathy genes in African Americans Ethn Dis 18 384 388 18785456
36. JB Kopp MW Smith GW Nelson, et al. 2008 MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis Nat Genet 40 1175 1184 18794856 10.1038/ng.226 1:CAS:528:DC%2BD1cXhtFKht77E
37. WH Kao MJ Klag LA Meoni, et al. 2008 MYH9 is associated with nondiabetic end-stage renal disease in African Americans Nat Genet 40 1185 1192 18794854 10.1038/ng.232 1:CAS:528:DC%2BD1cXhtFKht73O
38. AM Reeves-Daniel SS Iskandar DW Bowden, et al. 2010 Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report Am J Kidney Dis 55 e21 e24 20116156 10.1053/j.ajkd.2009.10.060
39. BI Freedman PJ Hicks MA Bostrom, et al. 2009 Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans Kidney Int 75 736 745 19177153 10.1038/ki.2008.701 1:CAS:528:DC%2BD1MXjtFaltbs%3D
40. BI Freedman PJ Hicks MA Bostrom, et al. 2009 Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD Nephrol Dial Transplant 11 3366 3371 10.1093/ndt/gfp316
41. I Gopalakrishnan SS Iskandar P Daeihagh, et al. 2011 Coincident idiopathic focal segmental glomerulosclerosis collapsing variant and diabetic nephropathy in an African American homozygous for MYH9 risk variants Hum Pathol 42 291 294 21074826 10.1016/j.humpath.2010.07.016
42. BI Freedman CD Langefeld L Lu, et al. 2011 Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans PLoS Genet 7 e1002150 21698141 10.1371/journal.pgen.1002150 1:CAS:528:DC%2BC3MXotVWgs74%3D This gene-gene interaction analysis assessed APOL1/MYH9 SNPs and nearly one million other genetic markers across the genome in African Americans with clinically diagnosed type 2 diabetic ESRD. Those with two MYH9 (or APOL1) risk variants did not demonstrate association with FRMD3, a diabetic nephropathy gene. Markers in FRMD3 were robustly associated in those lacking two chromosome 22q risk variants, revealing the potential to "genetically dissect" nondiabetic from diabetic ESRD in African Americans based on the presence of two MYH9 or APOL1 risk variants.
43. BI Freedman JB Kopp CA Winkler, et al. 2009 Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study Am J Nephrol 29 626 632 19153477 10.1159/000194791 1:CAS:528:DC%2BD1MXmslCis7c%3D
44. GW Nelson BI Freedman DW Bowden, et al. 2010 Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15 Hum Mol Genet 19 1805 1815 20124285 10.1093/hmg/ddq039 1:CAS:528:DC%2BC3cXksFKns78%3D
45. TK Oleksyk GW Nelson P An, et al. 2010 Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa PLoS One 5 e11474 20634883 10.1371/journal.pone.0011474 This study assessed SNPs in the MYH9 E haplotype block in a worldwide population survey of major continental populations using International HapMap Project and the Human Genome Diversity Panel data. The worldwide distribution and frequencies of risk/protective haplotypes were presented, relevant to public health implications, including in regions of the world with a high prevalence of HIV infection.
46. L Vanhamme F Paturiaux-Hanocq P Poelvoorde, et al. 2003 Apolipoprotein L-I is the trypanosome lytic factor of human serum Nature 422 83 87 12621437 10.1038/nature01461 1:CAS:528:DC%2BD3sXhs1yitL8%3D
47. E Pays B Vanhollebeke 2009 Human innate immunity against African trypanosomes Curr Opin Immunol 21 493 498 19559585 10.1016/j.coi.2009.05.024 1:CAS:528:DC%2BD1MXht1Gnu7fF
48. C Pattaro YS Aulchenko A Isaacs, et al. 2009 Genome-wide linkage analysis of serum creatinine in three isolated European populations Kidney Int 76 297 306 19387472 10.1038/ki.2009.135 1:CAS:528:DC%2BD1MXoslyitLw%3D
49. CM O'Seaghdha RS Parekh SJ Hwang, et al. 2011 The MYH9/APOL1 region and chronic kidney disease in European-Americans Hum Mol Genet 20 2450 2456 21429915 10.1093/hmg/ddr118 MYH9 E1 haplotype SNP rs4821480 and 282 SNPs in the MYH9/APOL1 region were tested for association with subclinical kidney disease in 13,133 European-derived participants from the Framingham Heart and Atherosclerosis Risk in Communities Studies. In a meta-analysis, only rs4821480 was associated with nondiabetic kidney disease. APOL1 G1 and G2 risk variants did not account for the observed MYH9 signal, as they were exceedingly rare in these European-derived populations. This suggests that MYH9 SNP rs4821480 is associated with risk of nondiabetic nephropathy in individuals of European ancestry.
50. Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Comeau ME, Divers J, Langefeld CD, Freedman BI, Bowden DW. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2011 Oct 3 (Epub ahead of print). doi: 10.1093/ndt/gfr522.
51. RW Steiner 2010 'Normal for now' or 'at future risk': a double standard for selecting young and older living kidney donors Am J Transplant 10 737 741 20199512 10.1111/j.1600-6143.2010.03023.x 1:STN:280:DC%2BC3c3ovFarug%3D%3D
52. HU Meier-Kriesche FK Port AO Ojo, et al. 2000 Effect of waiting time on renal transplant outcome Kidney Int 58 1311 1317 10972695 10.1046/j.1523-1755. 2000.00287.x 1:STN:280:DC%2BD3cvotlyiug%3D%3D
53. SJ Swanson IO Hypolite LY Agodoa, et al. 2002 Effect of donor factors on early graft survival in adult cadaveric renal transplantation Am J Transplant 2 68 75 12095059 10.1034/j.1600-6143.2002.020112.x
54. HA Chakkera AM O'Hare KL Johansen, et al. 2005 Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs J Am Soc Nephrol 16 269 277 15563568 10.1681/ASN.2004040333
55. CO Callender WS Cherikh P Traverso, et al. 2009 Effect of donor ethnicity on kidney survival in different recipient pairs: an analysis of the OPTN/UNOS database Transplant Proc 41 4125 4130 20005353 10.1016/j.transproceed.2009.06. 182 1:STN:280:DC%2BD1Mfitlyhsw%3D%3D
56. WS Cherikh CJ Young BF Kramer, et al. 2011 Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation Am J Transplant 11 1650 1655 21672160 10.1111/j.1600-6143.2011.03609.x 1:STN:280:DC%2BC3MjhvFGqtA%3D%3D
57. AM Reeves-Daniel JA Depalma AJ Bleyer, et al. 2011 The APOL1 gene and allograft survival after kidney transplantation Am J Transplant 11 1025 1030 21486385 10.1111/j.1600-6143.2011.03513.x 1:STN:280:DC%2BC3MvmvV2ruw%3D%3D Allograft survival was significantly impacted by the presence of APOL1 variants in African American deceased kidney donors. Kidneys donated by African Americans with two APOL1 risk variants functioned for shorter durations than those donated by individuals with fewer than two risk variants, and African American donor kidneys without two APOL1 risk variants functioned as long as those donated by European Americans. Hence, donor APOL1 genotype, not donor race, explained racial differences in renal allograft survival. If replicated, this study may alter practice patterns, including selection of (a) African American live kidney donors at lower risk for subsequent nephropathy, and (b) deceased kidneys with higher likelihood for long-term function.
58. CL Davis M Cooper 2010 The state of U.S. living kidney donors Clin J Am Soc Nephrol 5 1873 1880 20634322 10.2215/CJN.01510210
59. TR Srinivas 2011 Defining living kidney donor ESRD risk-looking beyond race and gender Am J Transplant 11 1556 1558 21672161 10.1111/j.1600-6143.2011. 03610.x 1:STN:280:DC%2BC3MjhvFGqtQ%3D%3D
60. JB Kopp CA Winkler GW Nelson 2010 MYH9 genetic variants associated with glomerular disease: What is the role for genetic testing? Semin Nephrol 30 409 417 20807613 10.1016/j.semnephrol.2010.06.007 1:CAS:528:DC%2BC3cXhtVymtrnJ
61. MA Bostrom BI Freedman 2010 The spectrum of MYH9-associated nephropathy Clin J Am Soc Nephrol 5 1107 1113 20299374 10.2215/CJN.08721209 1:CAS:528:DC%2BC3cXptV2mtLc%3D
62. BI Freedman JC Edberg ME Comeau, et al. 2010 The non-muscle myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans Am J Nephrol 32 66 72 20523037 10.1159/000314688 1:CAS:528:DC%2BC3cXptVSlu78%3D
63. CW McDonough ND Palmer PJ Hicks, et al. 2011 A genome-wide association study for diabetic nephropathy genes in African Americans Kidney Int 79 563 572 21150874 10.1038/ki.2010.467
64. MG Pezzolesi GD Poznik JC Mychaleckyj, et al. 2009 Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes Diabetes 58 6 1403 1410 19252134 10.2337/db08-1514 1:CAS:528: DC%2BD1MXntFanu78%3D
65. SM Gordon S Hofmann DS Askew WS Davidson 2011 High density lipoprotein: It's not just about lipid transport anymore Trends Endocrinol Metab 22 9 15 21067941 10.1016/j.tem.2010.10.001 1:CAS:528:DC%2BC3cXhs1Wqur%2FF
66. Freedman BI, Langefeld CD, Murea M, Ma L, Otvos J, Turner JJ, Antinozzi PA, Rocco M, Parks JS. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant 2011 Sep 19. (Epub ahead of print). doi: 10.1093/ndt/gfr542.
67. LH Kuller G Grandits JD Cohen, et al. 2007 Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome Atherosclerosis 195 122 128 17011566 10.1016/j.atherosclerosis.2006.09.001 1:CAS:528:DC%2BD2sXhtF2hur%2FP
68. M Sharma R Sharma ET McCarthy VJ Savin 1999 "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma J Am Soc Nephrol 10 552 561 10073606 1:CAS:528:DyaK1MXhsl2jtLs%3D
69. RY Gohh AF Yango PE Morrissey, et al. 2005 Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients Am J Transplant 5 2907 2912 16303004 10.1111/j.1600-6143.2005.01112.x 1:STN:280: DC%2BD2MnitFKmtA%3D%3D
70. G Candiano L Musante C Zennaro, et al. 2001 Inhibition of renal permeability towards albumin: a new function of apolipoproteins with possible pathogenetic relevance in focal glomerulosclerosis Electrophoresis 22 1819 1825 11425237 10.1002/1522-2683(200105)22:9<1819::AID-ELPS1819>3.0.CO;2-5 1:CAS:528:DC%2BD3MXksFKhsb8%3D
71. G Candiano L Musante M Carraro, et al. 2001 Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis J Am Soc Nephrol 12 143 150 11134260 1:CAS:528:DC%2BD3MXkvFKjsw%3D%3D
72. G Wan S Zhaorigetu Z Liu, et al. 2008 Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death J Biol Chem 283 21540 21549 18505729 10.1074/jbc.M800214200 1:CAS:528: DC%2BD1cXovFWrsLo%3D
73. RM Salem PE Cadman Y Chen, et al. 2008 Chromogranin A polymorphisms are associated with hypertensive renal disease J Am Soc Nephrol 19 600 614 18235090 10.1681/ASN.2007070754 1:CAS:528:DC%2BD1cXktVamt7o%3D
74. Fung MM, Salem RM, Lipkowitz MS, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant 2011 May 25 (Epub ahead of print). PMID: 21613384.
75. JA Dusel KP Burdon PJ Hicks, et al. 2005 Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease Kidney Int 68 256 262 15954915 10.1111/j.1523-1755.2005.00400.x 1:CAS:528:DC%2BD2MXmt1Cgt78%3D